First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and Diverse Oncology Pipeline “Nobel Prize-winning research led to the discovery of HIF-2α and its role in cancer. MK-6482 ...

WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not ...

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease. Sean Korbitz had his first bout with cancer — a brain tumor discovered after six ...

Researchers have mapped all the possible outcomes of changes to a tumor-suppressing gene called VHL, the first step in a huge research endeavor to unpick the outcomes of tens of thousands of genetic ...

Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. Background: Germline mutations in the VHL gene cause VHL syndrome. Functional loss of the VHL gene ...

Discovering different genetic mutations to target ... continues to add to the excitement. Targeted therapies are defined as drugs that block critical functions specific to cancer cells, selectively ...

PNAS is the world's most-cited multidisciplinary scientific serial. It publishes high-impact research reports, commentaries, perspectives, reviews, colloquium papers, and actions of the Academy. In ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted ...

Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL, the first step in a huge research endeavour to unpick the outcomes ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral ...